Page last updated: 2024-08-23

isosorbide-5-mononitrate and Cerebral Small Vessel Diseases

isosorbide-5-mononitrate has been researched along with Cerebral Small Vessel Diseases in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's3 (75.00)2.80

Authors

AuthorsStudies
Appleton, JP; Bath, PM; Blair, GW; Chappell, F; Doubal, FN; Flaherty, K; Hamilton, I; Janssen, E; Shi, Y; Stringer, MS; Thrippleton, MJ; Wardlaw, JM1
Bath, PM; Doubal, F; Mhlanga, I; Montgomery, AA; Oatey, K; Wardlaw, JM; Woodhouse, LJ1
Bamford, J; Bath, PM; Cvoro, V; Doubal, FN; England, T; Hassan, A; Heye, AK; Mhlanga, II; Montgomery, A; O'Brien, JT; Oatey, K; Roffe, C; Sprigg, N; Wardlaw, JM; Werring, DJ; Woodhouse, LJ1
Appleton, JP; Bath, PM; Blair, GW; Boyd, J; Dooley, R; Doubal, F; Flaherty, K; Hamilton, I; Law, ZK; Richardson, C; Shi, Y; Shuler, K; Sprigg, N; Stringer, M; Thrippleton, MJ; Wardlaw, JM1

Trials

4 trial(s) available for isosorbide-5-mononitrate and Cerebral Small Vessel Diseases

ArticleYear
Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial.
    Stroke, 2022, Volume: 53, Issue:1

    Topics: Aged; Cerebral Small Vessel Diseases; Cilostazol; Female; Hemodynamics; Humans; Isosorbide Dinitrate; Lipoproteins; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome; Vasodilator Agents

2022
Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850).
    Stroke and vascular neurology, 2023, Volume: 8, Issue:2

    Topics: Brain Ischemia; Cerebral Small Vessel Diseases; Cilostazol; Female; Humans; Middle Aged; Prospective Studies; Stroke; Stroke, Lacunar

2023
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial.
    JAMA neurology, 2023, 07-01, Volume: 80, Issue:7

    Topics: Aged; Cerebral Small Vessel Diseases; Cilostazol; Female; Humans; Male; Middle Aged; Quality of Life; Stroke; Stroke, Lacunar; Treatment Outcome

2023
Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mon
    International journal of stroke : official journal of the International Stroke Society, 2018, Volume: 13, Issue:5

    Topics: Age Factors; Cerebral Small Vessel Diseases; Cilostazol; Cognition Disorders; Dementia; Double-Blind Method; Female; Follow-Up Studies; Humans; Isosorbide Dinitrate; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Severity of Illness Index; Treatment Outcome; United Kingdom; Vasodilator Agents

2018